(2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [(R)-1-(tetrahydro-furan-2-yl)methyl]-amide | 929267-88-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [(R)-1-(tetrahydro-furan-2-yl)methyl]-amide
• 英文别名: (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-N-(tetrahydrofuran-2(R)-ylmethyl)nonamide；(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-N-[[(2R)-oxolan-2-yl]methyl]-2-propan-2-ylnonanamide
• CAS: 929267-88-9
• 化学式: C₃₀H₅₂N₂O₆
• 分子量: 536.753
• InChiKey: FITLCBYWYYWGNV-YUDMECHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-N-(tetrahydrofuran-2(R)-ylmethyl)nonamide 在 palladium on activated charcoal C.I.酸性橙108 作用下， 以 乙醇 为溶剂， 生成 (2S,4S,5S,7S)-5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid [(R)-1-(tetrahydro-furan-2-yl)methyl]-amide
  参考文献：
  名称：

  Alcanoic Acid Amides Substituted by Saturated O-Heterocycles

  摘要：

  通式为（式I）的化合物，其中取代基R1至R6的含义如权利要求1所示，具有抑制肾素的性质，可用作药物。

  公开号：

  US20090275651A1

文献信息

• Organic Compounds
  申请人：Maibaum Juergen Klaus

  公开号：US20090076062A1

  公开（公告）日：2009-03-19

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  揭示了具有抑制肾素作用的δ-氨基-γ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包括这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌梗死后心肌病、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾病、肝纤维化、糖尿病并发症（如肾病、血管病和神经病变）、冠状血管疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆症、焦虑状态和认知障碍的治疗方法。
• Alcanoic Acid Amides Substituted by Saturated O-Heterocycles
  申请人：Herold Peter

  公开号：US20090275651A1

  公开（公告）日：2009-11-05

  Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1 , have renin-inhibiting properties and can be used as medicines.

  通式为（式I）的化合物，其中取代基R1至R6的含义如权利要求1所示，具有抑制肾素的性质，可用作药物。
• ORGANIC COMPOUNDS
  申请人：Maibaum Juergen Klaus

  公开号：US20120022100A1

  公开（公告）日：2012-01-26

  Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  本申请公开了具有肾素抑制作用的公式（I）及其盐的δ-氨基-γ-羟基-ω-芳基-脂肪酸酰胺化合物。还公开了包含这些化合物的制药组合物和治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥厚、心脏纤维化、心肌梗死后的心肌病、舒张功能障碍、慢性肾脏疾病、肝纤维化、糖尿病引起的并发症，如肾病、血管病和神经病，冠状血管疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮血症、认知障碍、老年痴呆、焦虑状态和认知障碍的治疗方法。
• US8058307B2
  申请人：——

  公开号：US8058307B2

  公开（公告）日：2011-11-15
• ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES
  申请人：Novartis AG

  公开号：EP1937248B1

  公开（公告）日：2010-06-02